Global Prothrombin Complex Concentrate(PCC) Market Research Report 2022

Mainly used to treat congenital and acquired coagulation factor II, VII, IX, and X deficiencies (alone or in combination) including: coagulation factor IX deficiency (hemophilia B), and coagulation factor II, VII, X deficiency overdose of anticoagulants, vitamin K deficiency; patients with hemorrhage caused by liver disease need to correct coagulation dysfunction; when disseminated intravascular coagulation (DIC) occurs, coagulation factors II, VII, IX, and X are consumed in large quantities, which can be used in heparin Application after chemotherapeutic; prothrombin time prolongation due to various reasons and intended for surgery, but may be ineffective for those with coagulation factor V deficiency; treatment of bleeding symptoms in patients with hemophilia A who have produced factor VIII preparations ; Reversal of coumarin anticoagulant-induced bleeding.
Due to the COVID-19 pandemic, the global Prothrombin Complex Concentrate(PCC) market size is estimated to be worth US$ million in 2021 and is forecast to a readjusted size of US$ million by 2028 with a CAGR of % during the forecast period 2022-2028. Fully considering the economic change by this health crisis, the Europe Prothrombin Complex Concentrate(PCC) market is estimated at US$ million in 2022, while the United States and China are forecast to reach US$ million and US$ million by 2028, respectively. The proportion of the United States is % in 2022, while Chinese percentage is %, and it is predicted that China market share will reach % in 2028, trailing a CAGR of % through the analysis period. As for the Europe Prothrombin Complex Concentrate(PCC) landscape, Germany is projected to reach US$ million by 2028. and in Asia, the notable markets are Japan and South Korea, CAGR is % and % respectively for the next 6-year period.
100IU accounting for % of the Prothrombin Complex Concentrate(PCC) global market in 2021, is projected to value US$ million by 2028, growing at a revised % CAGR from 2022 to 2028. While Hopistial segment is altered to an % CAGR throughout this forecast period and will hold a share about % in 2028.
The global major manufacturers of Prothrombin Complex Concentrate(PCC) include CSL, Beijing Tiantan Biological Products, SHANGHAI RAAS, Biotest, Taibang Biologic Group, HUALAN BIOLOGICAL ENGINEERING, WEIGUANG BIOLOGICAL, Green Cross and BOHUI, etc. In terms of revenue, the global 3 largest players have a % market share of Prothrombin Complex Concentrate(PCC) in 2021.
This report focuses on Prothrombin Complex Concentrate(PCC) volume and value at the global level, regional level, and company level. From a global perspective, this report represents overall Prothrombin Complex Concentrate(PCC) market size by analysing historical data and future prospect. Regionally, this report focuses on several key regions: North America, Europe, China and Japan, etc.
Global Prothrombin Complex Concentrate(PCC) Market: Segment Analysis
The research report includes specific segments by region (country), by company, by Type and by Application. This study provides information about the sales and revenue during the historic and forecasted period of 2017 to 2028. Understanding the segments helps in identifying the importance of different factors that aid the market growth.
Segment by Type
100IU
200IU
300IU
400IU
1000IU
Segment by Application
Hopistial
Clinic
Others
By Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
By Company
CSL
Beijing Tiantan Biological Products
SHANGHAI RAAS
Biotest
Taibang Biologic Group
HUALAN BIOLOGICAL ENGINEERING
WEIGUANG BIOLOGICAL
Green Cross
BOHUI
Guangdong Shuanglin Biopharmaceutical
Jiangxi Boya Bio-Pharmaceutical